The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients
Abstract
Purpose: To evaluate HER-2 expression and amplification in a large cohort of endometrial cancer with complete surgical staging and outcome data. Patients and Methods: A tissue microarray was constructed of 483 patients with endometrial cancer of diverse histologic type and stage and tested for HER-2 expression and amplification using current standards of practice. There was outcome data for 83% of all patients and 81% with complete surgical staging. Results: Both expression and amplification of HER-2 was associated with high-grade (P = .0001) and high stage (P = .0001) endometrial cancer. The highest rate of HER-2 expression and amplification was seen in serous carcinoma (43% and 29%), while grade 1 endometrioid adenocarcinoma showed the lowest levels (3% and 1%). For all histologic types, the rate of HER-2 expression and amplification was remarkably different (P < .0001) for grade 3 cancers (31% and 15%) versus grade 2 (7% and 3%) and grade 1 cancers (3% and 1%), with similar results for endometrioid type (P < .0001). Both HER-2 expression and amplification correlated with disease-specific survival and progression-free survival in univariate analyses. By multivariate analysis HER-2 expression in the presence of amplification (P = .012) correlated with overall survival, but not expression in the absence of amplification. Overall survival was significantly shorter (P = .0001) in patients who overexpressed (median, 5.2 years) and/or showed amplification of HER-2 (median, 3.5 years) versus those that did not (median of all cases, 13 years). Conclusion: Our results would suggest that HER-2 is an important oncogene in high grade and stage endometrial cancer, but plays only a minor role in the much more common low grade and stage tumors that encompass the majority of clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 582
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 457
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441
Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis
Rubin, M. A., Dunn, R., Strawderman, M., & Pienta, K. J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200203000-00004 · Cited by 318
Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma
Slomovitz, B. M., Broaddus, R. R., Burke, T. W., Sneige, N., Soliman, P. T., Wu, W., Sun, C. C., Munsell, M. F., Gershenson, D. M., & Lu, K. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.154 · Cited by 219
Khalifa, M. A., Mannel, R. S., Haraway, S. D., Walker, J., & Min, K.-W. (1994) · Gynecologic Oncology · doi:10.1006/gyno.1994.1092 · Cited by 162
Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer
Lukes, A. S., Kohler, M. F., Pieper, C. F., Kerns, B. J., Bentley, R. C., Rodriguez, G. C., Soper, J. T., Clarke‐Pearson, D. L., Bast, R. C., & Berchuck, A. (1994) · Cancer · Cited by 154
Saffari, B., Jones, L. A., El‐Naggar, A. K., et al. (1995) · PubMed · Cited by 145
Cited by
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Slomovitz, B. M., & Coleman, R. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0662 · Cited by 397
Tsurutani, J., Iwata, H., Krop, I., Jänne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 354
Amant, F., Mirza, M. R., & Creutzberg, C. L. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60024-1 · Cited by 309
Metadata
- Authors
- Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-20
- Volume
- 24
- Issue
- 15
- Pages
- 2376-2385
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2069451423
- Cited by
- 258
- References
- 14
- FWCI
- 17.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients. https://app.cochat.ai/papers/10.1200/jco.2005.03.4827
- The paper
- Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M. (2006). HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.03.4827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.